
LIRA‐PRIME (NCT02730377), a randomized open‐label trial, compared efficacy of liraglutide in controlling glycemia versus an oral antidiabetic drug (OAD) in patients with uncontrolled type 2 diabetes (T2D) despite metformin use in a primary care setting (n=219 sites, n=9 countries). Glycemic control was better maintained with liraglutide versus OAD, supporting liraglutide use when intensifying therapy in primary care patients with T2D.
Like
Save
Share